18F-DOPA PET/CT in neuroblastoma: Comparison of conventional imaging with CT/MR

Clinical Nuclear Medicine

Volumn 37, Issue 4, 2012, Pages

  Lopci, Egesta ^a,b   Piccardo, Arnoldo ^c   Nanni, Cristina ^a   Altrinetti, Vania ^c   Garaventa, Alberto ^d   Pession, Andrea ^a   Cistaro, Angelina ^e   Chiti, Arturo ^b   Villavecchia, Giampiero ^c   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d G GASLINI INSTITUTE   (Italy)

^e IRMET   (Italy)

Author keywords

18F DOPA, PET CT; CT; MR; neuroblastoma

Indexed keywords

6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; CLINICAL TRIAL; COMPARATIVE STUDY; NEUROENDOCRINE TUMOR; SCINTISCANNING;

CHILD; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROBLASTOMA; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84858147946     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182485172     Document Type: Article

References (28)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: JB Lippincott; 1997:29-761.
2. Ley S, Ley-Zaporozhan J, Günther P, et al. Neuroblastoma imaging. Rofo. 2011;183:217-225.
3. Tateishi U, Hasegawa T, Makimoto A, et al. Adult neuroblastoma: radiologic and clinicopathologic features. J Comput Assist Tomogr. 2003;27:321-326. (Pubitemid 36793179)
4. Pearce AG. The cytochemistry and ultrastructure of polypeptide hormoneproducing cells of the APUD series and the embryologic, physiologic implications of the concept. J Histochem Cytochem. 1969;17:303-313.
5. LaBrosse EH, Comoy E, Bohuon C, et al. Catecholamine metabolism in neuroblastoma. J Natl Cancer Inst. 1976;57:633-638.
6. Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med Mol Imaging. 2001;28: 64-71. (Pubitemid 32120808)
7. Becherer A, Szabó M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med. 2004;45:1161-1167. (Pubitemid 47611661)
8. Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728-734. (Pubitemid 44283659)
9. Jager PL, Chirakal R, Marriott CJ, et al. 6-L-18F- fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med. 2008;49:573-586. (Pubitemid 351520605)
10. Minn H, Kauhanen S, Seppanen M, et al. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50:1915-1918.
11. Gazdar AF, Helman LJ, Israel MA, et al. Expression of neuroendocrine cell markers L-dopadecarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988;48: 4078-4082.
12. Imani F, Agopian VG, Auerbach MS, et al. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-519.
13. Barthlen W, Blankenstein O, Mau H, et al. Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2008;93:869-875. (Pubitemid 351398565)
14. Nanni C, Rubello D, Castellucci P, et al. 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours. Biomed Pharmacother. 2006;60: 593-606. (Pubitemid 44740369)
15. Leu S, Tzen KY. Demonstrating different molecular components in neuroblastoma using 18F-FDOPA PET-18F-FDG PET coregistration with color coding. J Nucl Med. 2010;51:1659.
16. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-1477. (Pubitemid 23228250)
17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577. (Pubitemid 23118304)
18. Siegel MJ, Ishwaran H, Fletcher BD, et al. Staging of neuroblastoma at imaging: report of the Radiology Diagnostic Oncology Group. Radiology. 2002;223:168-175. (Pubitemid 34258205)
19. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med. 2004;45:1172-1188. (Pubitemid 47611663)
20. Howman-Giles R, Shaw PJ, Uren RF, et al. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med. 2007;37:286-302. (Pubitemid 46828965)
21. Tanabe M, Takahashi H, Ohnuma N, et al. Evaluation of bone marrow metastases of neuroblastoma and changes after chemotherapy by MRI. Med Pediatr Oncol. 1993;21:54-59. (Pubitemid 23018177)
22. Sofka CM, Semelka RC, Kelekis NL, et al. Magnetic resonance imaging of neuroblastoma using current techniques. Magn Reson Imaging. 1999;17:193-198. (Pubitemid 29053177)
23. Pfluger T, Schmied Cand C, Porn U, et al. Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. Am J Roentgenol. 2002; 181:1115-1124. (Pubitemid 37151800)
24. Lebtahi N, Gudinchet F, Nenadov-Beck M, et al. Evaluating bone marrow metastasis of neuroblastoma with iodine-123-MIBG scintigraphy and MRI. J Nucl Med. 1997;38:1389-1392. (Pubitemid 27386197)
25. Goo HW, Choi SH, Ghim T, et al. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol. 2005;35:766-773. (Pubitemid 41131176)
26. Fiebrich HB, Brouwers AH, Kerstens MN, et al. 6-[F-18]Fluoro- Ldihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)Imetaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94:3922-3930.
27. Luster M, Karges W, Zeich K, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18FDOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging. 2010;37:484-493.
28. Ambrosini V, Tomassetti P, Rubello D, et al. Role of 18F-DOPA PET/CT imaging in the management of patients with 111In-pentreotide negative GEP tumours. Nucl Med Commun. 2007;28:473-477. (Pubitemid 46684197)